Form 4: AbbVie EVP Sells $2.6M in Stock

AbbVie Inc.'s EVP, Chief Business and Strategy Officer, Nicholas Donoghoe, sold over 13,000 shares of common stock for approximately $2.6 million in pre-planned transactions.

Summary

• Nicholas Donoghoe, Executive Vice President and Chief Business and Strategy Officer of AbbVie Inc. (ABBV), reported the sale of common stock.
• On August 5, 2025, Donoghoe sold 3,234.17 shares of AbbVie common stock at a weighted average price of $198.27 per share, with prices ranging from $198.26 to $198.37.
• On the same date, August 5, 2025, an additional 10,061 shares were sold at a weighted average price of $198.59 per share, with prices ranging from $198.56 to $198.73.
• The total number of shares sold across both transactions was 13,295.17.
• The total approximate value of the shares sold is $2,638,200.
• Following these transactions, Nicholas Donoghoe beneficially owns 58,247 shares of AbbVie common stock.
• The transactions were made pursuant to a Rule 10b5-1(c) pre-planned contract or instruction for the sale of equity securities.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, the disclosure indicates these were pre-planned transactions under a Rule 10b5-1 plan, which suggests a routine financial management decision rather than a reaction to specific company news or a lack of confidence.

Negatives

• An executive selling a significant number of shares, even if pre-planned, can sometimes be perceived as a lack of confidence by some investors, though it is a routine event for many executives.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing reports a routine insider transaction and does not provide broader industry context or trends. It is specific to the individual executive and AbbVie Inc.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive could be interpreted in various ways, but given it's a pre-planned transaction, the direct impact on shareholder sentiment is likely minimal unless it's part of a larger pattern of insider selling.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned sale of shares by an executive. Such transactions are common for compensation and personal financial planning and do not typically signal a fundamental change in the company's prospects or warrant a change in investment thesis. Investors should consider this a standard disclosure rather than a strong buy or sell signal.

Keywords

AbbVie, ABBV, SEC Form 4, Insider Trading, Stock Sale, Executive Compensation, Nicholas Donoghoe, Pharmaceutical, Biotech